Is gene therapy the answer for prostate cancer?

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Prostate cancer is a leading cause of cancer diagnoses in men globally.
• Current treatments lack curative options for advanced and metastatic prostate cancer.
• The prostate's accessibility and molecular understanding make it a target for gene therapy.

Purpose of the Study:

• To review the progress and potential of gene therapy for prostate cancer.
• To categorize current therapeutic approaches in prostate cancer gene therapy.
• To highlight the status of ongoing clinical trials.

Main Methods:

• Review of current research and clinical trial data for prostate cancer gene therapy.
• Categorization of therapeutic strategies into corrective and cytoreductive/cytolytic approaches.
• Analysis of progress in gene transfer vectors and prostate-targeting strategies.

Main Results:

• Significant advancements in gene transfer vectors and targeting strategies have been achieved.
• Two main categories of therapeutic approaches are under investigation: corrective and cytoreductive/cytolytic.
• Sixty-three clinical trials for prostate cancer gene therapy are registered in the US and UK.

Conclusions:

• Gene therapy holds significant potential as a future treatment for prostate cancer.
• Despite remaining challenges, early clinical trial outcomes are encouraging.
• Further development may establish gene therapy as a key modality for prostate cancer treatment.